

Date: DD: MM: YYYY

**Urgent Field Safety Notice**  
**Device Commercial Name**

For Attention of

Contact details of local representative	
Name	
Address	
Email address	
Telephone number	

Approved by Fredrik Mirenborn 2022-Mar-30 15:45 CET  
Doc.no. 758187 Ver. 1.0 Page 1 (6)



**Urgent Field Safety Notice (FSN)**

**Device Commercial Name**  
**Risk addressed by FSN**

<b>1. Information of affected device(s)</b>	
1.1	Device Types(s)  Phadia™ Instrument
1.2	Commercial name(s)  Phadia 200
1.3	Unique Device Identifier(s) (UDI-DI)  07333066016900
1.4	Primary clinical purpose of device(s)  Phadia 200 is a fully automated instrument including software to be used together with dedicated in vitro diagnostic tests. The instrument is designed to handle processing of samples, reagents and calculation of analytical results from the measurement values. Phadia 200 is intended to be used in clinical laboratories.
1.5	Device Model/Catalogue/ part number(s)  12-4300-00
1.6	Affected serial or lot number range  All serial numbers

Approved by Fredrik Mirenborn 2022-Mar-30 15:45 CET  
 Doc.no. 758187 Ver. 1.0 Page 2 (6)



<b>2. Reason for Field Safety Corrective Action (FSCA)</b>	
2.1	<p>Description of the problem</p> <p>An issue in the Phadia 200 software can cause the pipette to be placed too high above the dilution plate. This may cause the sample and diluent not being mixed properly and/or splashing of sample into other dilution wells. This can cause results to be between 7-230 % of the true value and may cause false negative or false positive results.</p> <p>ImmunoCAP™ and EliA™ test results may be affected if the following dilutions and tube settings are used:</p> <ul style="list-style-type: none"> <li>• 1:50</li> <li>• 1:100</li> <li>• 1:200</li> <li>• Tube setting with a bottom thickness &gt;5 mm</li> </ul> <p>ImmunoCAP and EliA tests that includes sample dilution according to these criteria are listed in appendix 1.</p>
2.2	<p>Hazards giving rise to the FSCA</p> <p>The issue may give false test results which may lead to the necessity of medical or surgical intervention. No residual risk for false test results if action is taken.</p>
2.3	<p>Probability of problem arising</p> <p>The frequency of possibly affected EliA tests when using tube settings with a bottom thickness &gt;5 mm was estimated to be:</p> <ul style="list-style-type: none"> <li>• 6 % (7908 possibly affected tests / 131 370 total number of tests)</li> </ul> <p>For ImmunoCAP Specific IgG, the frequency of possibly affected tests when using tube settings with a bottom thickness &gt;5 mm was estimated to be:</p> <ul style="list-style-type: none"> <li>• 7 % (358 possibly affected tests / 5000 total number of tests)</li> </ul>
2.4	<p>Predicted risk to patient/ users</p> <p>The probability for serious injury due to falsely decreased or increased EliA or ImmunoCAP Specific IgG results is estimated to be remote</p>

Approved by Fredrik Mireborn 2022-Mar-30 15:45 CET  
 Doc.no. 758187 Ver. 1.0 Page 3 (6)



**3. Type of Action to mitigate the risk**

3.1	<p>Action(s) to be taken by the user</p> <p><input type="checkbox"/> Identify Device   <input type="checkbox"/> Quarantine Device   <input type="checkbox"/> Return Device   <input type="checkbox"/> Destroy Device</p> <p><input type="checkbox"/> On-site device modification/inspection</p> <p><input type="checkbox"/> Follow patient management recommendations</p> <p><input type="checkbox"/> Take note of amendment/reinforcement of instructions for use (IFU)</p> <p><input checked="" type="checkbox"/> Other A member of our Technical Support staff will contact you to schedule a visit to correct your instrument's tube settings and to investigate and inform you of possibly affected test results. If any possibly affected test results are identified, please determine if retesting of the samples is needed according to your internal operating procedures. Sign and return Customer Reply form FSN2022-02.</p> <p><input type="checkbox"/> None</p>
3.2	<p>Is customer reply required?</p> <p>Yes</p>
3.3	<p>Action(s) to be taken by the manufacturer</p> <p><input type="checkbox"/> Product removal   <input checked="" type="checkbox"/> On-site device modification/ inspection</p> <p><input type="checkbox"/> Software upgrade   <input type="checkbox"/> IFU or labeling change</p> <p><input checked="" type="checkbox"/> Other Corrective and preventive actions (CAPA) have been initiated to prevent this from recurring. The tube settings must be checked and changed on the Phadia 200 instrument. A search for potentially incorrect test results should be performed.</p> <p><input type="checkbox"/> None</p>

Approved by Fredrik Mireborn 2022-Mar-30 15:45 CET  
 Doc.no. 758187 Ver. 1.0 Page 4 (6)



4. General information	
4.1	FSN type New
4.2	Manufacturer information
	Company name Phadia AB
	Address Rapsgatan 7P, PO Box 6460 75137 Uppsala, Sweden
4.3	The Competent (Regulatory) Authority of your country has been informed about this communication to customers
4.4	List of attachments/ appendices: <ul style="list-style-type: none"> <li>List of tests that may be affected by QA2022-02</li> <li>Customer Reply Form FSN2022-02</li> </ul>
4.5	Name:
	Title:
	Signature:

Approved by Fredrik Mirenborn 2022-Mar-30 15:45 CET  
 Doc.no. 758187 Ver. 1.0 Page 5 (6)



Transmission of this Field Safety Notice	
	This notice needs to be passed on all those who need to be aware within your organization or to any organization where the potentially affected devices have been transferred. (As appropriate)
	Please transfer this notice to other organizations on which this action has an impact. (As appropriate)
	Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.
	Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback. *

Document name Field Safety Notice(FSN), FSN2022-02  
Number 758187 Version 1.0

Issued by Linus Carlsson-Forslund 2022-Mar-30 14:03 CET

Reviewed by Lisa Rohbe 2022-Mar-30 14:41 CET

Approved by Fredrik Mirenborn 2022-Mar-30 15:45 CET  
Release Date 2022-Mar-30 15:45 CET

